U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937749) titled 'A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on April 07.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of IBI362 in MASH subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 8-week screening period, a 60-week double-blind treatment period, and a 4-week follow-up period.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Intervention:
DRUG: ...